Skip to main content

Complement C5 Antibody (561)

Novus Biologicals, part of Bio-Techne | Catalog # NBP1-60147

Novus Biologicals, part of Bio-Techne
Catalog #
Availability
Size / Price
Qty
Loading...
NBP1-60147-0.05mg

Key Product Details

Species Reactivity

Human

Applications

ELISA, Functional, Immunoassay

Label

Unconjugated

Antibody Source

Monoclonal Mouse IgG2A Clone # 561

Concentration

0.1 mg/ml

Product Specifications

Immunogen

Human C5/C5a

Specificity

Monoclonal antibody 561 recognizes the N-terminus of C5. The antibody reacts both with intact C5 (190 kDa) as with C5a (115 kDa).

Clonality

Monoclonal

Host

Mouse

Isotype

IgG2A

Applications for Complement C5 Antibody (561)

Application
Recommended Usage

ELISA

detection
Application Notes
This antibody works in Functional, Immunoassay. The typical starting working dilution is 1:50. For neutralization of biological activity in vitro dilutions have to be made according to the amounts of C5/C5a to be inactivated.

Formulation, Preparation, and Storage

Purification

Protein A or G purified

Formulation

0.2 um filtered solution in PBS and 0.1% BSA

Preservative

No Preservative

Concentration

0.1 mg/ml

Shipping

The product is shipped with polar packs. Upon receipt, store it immediately at the temperature recommended below.

Stability & Storage

Store at 4C.

Background: Complement C5

The complement system is composed of over 30 proteins, activated in response to tissue injury, invading pathogens or other foreign surfaces. The complement pathways can be divided in the activation pathways and lytic pathway. The activation pathways lead via C3 to the cleavage of the fifth complement component C5 into C5a and C5b, resulting in activation of the lytic pahway C5a was first described as a cleavage product of C5 with chemotactic and anaphylatoxic properties. Further characterization revealed that C5a is an essential part of the innate immune response and evidence now suggests that it may also play a role in adaptive immunity. Complement fragment C5a is a 74 residue pro-inflammatory polypeptide. C5a induces smooth muscle contraction, increases vascular permeability, causes degranulation of mast cells and basophils, and release of lysosomal enzymes. In addition C5a stimulates the directed migration of neutrophils, eosinophils, basophils and monocytes. C5a binds to at least two seven-transmembrane domain receptors, C5aR (C5R1, CD88) and C5L2 (gpr77), expressed ubiquitously on a wide variety of cells but particularly on the surface of immune cells like macrophages, neutrophils and T cells. The former is a well-established receptor that initiates G-protein-coupled signaling via mitogen-activated protein kinase pathways, thereby by inducing synthesis of cytokines such as TNF-alpha, IL-1beta, IL-6 and IL-8. Its in vivo blockade greatly reduces inflammatory injury. Much less is known about C5L2, occupancy of which by C5a does not initiate increased intracellular Ca(2+).The widespread expression of C5a receptors throughout the body allows C5a to elicit a broad range of effects. Thus, C5a has been found to be a significant pathogenic driver in a number of immuno-inflammatory diseases. Nowadays C5a is also implicated in non-immunological functions associated with developmental biology, CNS development and neurodegeneration, tissue regeneration, and haematopoiesis.

Alternate Names

anaphylatoxin C5a analog, C3 and PZP-like alpha-2-macroglobulin domain-containing protein 4, C5, complement C5, complement component 5, CPAMD4MGC142298, FLJ17816, FLJ17822

Entrez Gene IDs

727 (Human)

Gene Symbol

C5

UniProt

Additional Complement C5 Products

Product Documents for Complement C5 Antibody (561)

Certificate of Analysis

To download a Certificate of Analysis, please enter a lot number in the search box below.

Product Specific Notices for Complement C5 Antibody (561)

This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.

Loading...
Loading...
Loading...
Loading...
Loading...